Quick Answer: Weight gain on tirzepatide is uncommon, as clinical trials show average weight losses of 1521%, but may occur due to medication non-adherence, concurrent weight-promoting drugs, fluid retention, dietary factors, or normal physiological fluctuations
Against placebo, Tirzepatide resulted in a weight loss of 9.1 kilograms, Semaglutide 2.8, EBID 1.8, and Liraglutide 1.2
Weight Loss Support L-Carnitine may support weight management by facilitating the burning of stored fat for energy
We screen every patient at our Rockaway and Morristown locations for personal and family histories of thyroid C-cell tumors
Ideal candidates for semaglutide include: Adults with type 2 diabetes (Ozempic and Rybelsus) Adults who have established heart and blood vessel-related disease or those who are at risk of developing these diseases or heart failure (Ozempic) Adults with chronic kidney disease and type 2 diabetes, to reduce the risk of worsening kidney disease or end-stage renal disease (Ozempic) Children aged 12 or more, adolescents, and adults with obesity (BMI 30 or more) and overweight (BMI 27 or more) with at least one weight-related complication, such as hypercholesterolemia, hyperlipidemia, heart disease, and hypertension (Wegovy) Patients with metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver scarring or fibrosis, but they should not have cirrhosis (Wegovy) Head-to-head comparison: Metformin vs
Association between polymorphisms in glutathione peroxidase and selenoprotein P genes, glutathione peroxidase activity, HRT use and breast cancer risk